

# Developments in the Management of Type 2 Diabetes

**This 24/7 Web Archive program will be available October 27, 2006 through December 31, 2006.**

There are approximately 21 million patients with diabetes in the United States; and the number of diagnosed cases is expected to double by 2050. Of these diagnosed patients, 90-95% have type 2 diabetes. Type 2 diabetes takes a tremendous toll on patients in the United States. Patients with type 2 diabetes have a 2-4 fold increased risk of stroke or death due to heart disease. Type 2 diabetes is the #1 cause of kidney failure and new cases of blindness among adults aged 20 to 74.

During this symposium prominent thought leaders will discuss important concepts in the clinical management of type 2 diabetes. "Understanding A1C: The Hidden Complexities" will help broaden understanding of the complexities and significance of A1C. There will be discussion of the physiology and pathophysiology of type 2 diabetes and strategies for managing getting patients to goal. In addition, recent developments in the management of type 2 diabetes will be presented.

## Learning Objectives

### Understanding A1C: The Hidden Complexities

- Understand physiological regulation of glucose homeostasis and major pathophysiological defects in type 2 diabetes
- Review the role of incretins in glucose homeostasis
- Understand complexities of elevated A1C
- Understand the treatment paradigm relating to getting the patient to A1C goal

### Recent Developments in the Management of Type 2 Diabetes

- To review recent developments in the management of type 2 diabetes

## 24/7 WEB ARCHIVE

Log in at [www.diabetesprogram2006.com](http://www.diabetesprogram2006.com) to review the full broadcast presentation.

For technical assistance with the web archive, please email [webhelp@diabetesprogram2006.com](mailto:webhelp@diabetesprogram2006.com)

**[www.diabetesprogram2006.com](http://www.diabetesprogram2006.com)**

20652001(8)-10/06-JAN  
Copyright ©2006 Merck & Co., Inc. Printed in USA.

## FACULTY

### Lawrence Blonde, MD, FACP, FACE

Lawrence Blonde, MD, FACP, FACE, is Director of the Ochsner Diabetes Clinical Research Unit in the Department of Endocrinology, Diabetes and Metabolism, and an Associate Internal Medicine Residency Program Director at the Ochsner Clinic Foundation in New Orleans, LA. His research activities have focused on new therapies and healthcare delivery systems for people with diabetes mellitus. He is board certified in internal medicine, nuclear medicine, and endocrinology. Dr. Blonde is the chair of the Steering Committee of the National Diabetes Education Program, a partnership of the National Institutes of Health, the Centers for Disease Control and Prevention, and more than 200 public and private organizations. He is also a member of the Board of Directors of the American Association of Clinical Endocrinologists (AACE) and is a current member and former chair of the ADA Professional Practice Committee, which develops practice guidelines for the care of people with diabetes.

### Willa A. Hsueh, MD

Dr. Willa A. Hsueh is Chief of Endocrinology, Diabetes, and Hypertension at UCLA Medical Center. Dr. Hsueh attended Ohio State University, completed a residency at Johns Hopkins and received postgraduate training in Endocrinology at Johns Hopkins. Dr. Hsueh is Board Certified in the areas of Internal Medicine and Endocrinology. Dr. Hsueh has been published in various scientific journals, including *Kidney International* and *Diabetes*. In addition, Dr. Hsueh serves on the editorial board of *Diabetes*.

### Peter P. Stein, MD

Peter P. Stein, MD is a Senior Director in the Clinical Research Metabolism group at Merck Research Laboratories. He completed medical school, residency, and fellowship at Yale University School of Medicine, before joining the faculty at that institution. He was Section Chief in Endocrinology and Metabolism at the Medical College of Georgia, before joining Bristol-Myers-Squibb where he worked on diabetes drug development. He joined Merck in 2000, and has continued to focus on the development of new medications to treat patients with type 2 diabetes.